Tiny nanowire implant aims to restore sight in rare eye disease

NCT ID NCT05853107

Recruiting now Disease control Sponsor: Eye & ENT Hospital of Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This pilot study is testing a new retinal implant called AuTNA I in 7 people with retinitis pigmentosa, a genetic condition that causes progressive vision loss. The implant, a tiny array of nanowires placed under the retina, is designed to replace damaged light-sensing cells. Researchers will check safety and measure any vision improvements over one year using eye tests, brain scans, and electrical activity tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AuTNA I retinal prosthesis (nanoparticle-decorated titanium dioxide nanowire array device implanted under the retina)
What this could lead to: If successful, this could offer a new way to restore some vision in people with retinitis pigmentosa who have lost sight.
What could go wrong: This is a very early pilot study with only 7 people, so results may not apply widely. The implant is a new device, and risks like surgical complications or lack of vision improvement are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

retinitis pigmentosa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RETINITIS PIGMENTOSA

Contacts and locations

Locations

Chunhui Jiang
RECRUITING

Shanghai, Shanghai Municipality, 200030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.